SABR hits efficacy, safety targets for NSCLC with interstitial lung disease
In the treatment of patients with interstitial lung disease (ILD) and early-stage non–small cell lung cancer (NSCLC), stereotactic ablative radiotherapy (SABR) has met the prespecified acceptability thresholds for both toxicity and efficacy, according to the single-arm, phase II ASPIRE-ILD study.
